Literature DB >> 8556494

Comparison of corticosteroid- and L3T4+ antibody-immunosuppressed mouse models of Pneumocystis carinii pneumonia for evaluation of drugs and leukocytes.

M S Bartlett1, W L Current, A Orazi, N L Bauer, R S Neiman, S F Queener, J W Smith.   

Abstract

An immunologically immunosuppressed mouse model of Pneumocystis carinii pneumonia using antibody developed by Dialynas et al. (Immunol. Rev. 74:29-55, 1983) directed to L3T4+ T cells (referred to as L3T4+ antibody) was compared with a corticosteroid-immunosuppressed mouse model. Corticosteroid- or L3T4+ antibody-immunosuppressed BALB/c mice transtracheally inoculated with P. carinii developed severe infections within 5 weeks after inoculation and responded to treatments with an echinocandin B analog, LY302146, or trimethoprim plus sulfamethoxazole so that they had decreased numbers of P. carinii cysts and trophozoites. LY302146 appeared to be more effective in L3T4+ antibody-immunosuppressed mice than in dexamethasone-immunosuppressed mice. Leukocyte populations in lungs of both mouse models during development of infection and during treatment were compared by using immune cell-specific staining. Lungs of L3T4+ antibody-immunosuppressed mice had many more cells detected with pan-B antibody and pan-T antibody than dexamethasone-immunosuppressed mice and the lungs of successfully treated mice had about the same numbers of macrophages as those of nonimmunosuppressed uninfected mice. The immunologically immunosuppressed model will allow study of cytokines and other immune modulators alone and in combination with drugs.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8556494      PMCID: PMC368325          DOI: 10.1128/cdli.1.5.511-516.1994

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  28 in total

Review 1.  Prophylaxis of Pneumocystis carinii pneumonia: an update.

Authors:  J A Kovacs; H Masur
Journal:  J Infect Dis       Date:  1989-11       Impact factor: 5.226

2.  Increased susceptibility to inoculated Lewis lung carcinoma (3LL) but unaltered tumor growth in mice treated with monoclonal antibody to L3T4 on mouse T-helper cells.

Authors:  W B Ershler; R G Klopp; A L Moore; S L Krauss; G Ranges
Journal:  Cancer Invest       Date:  1989       Impact factor: 2.176

3.  Identification of Pneumocystis carinii in immunodeficient mice.

Authors:  J P Sundberg; T Burnstein; L D Shultz; H Bedigian
Journal:  Lab Anim Sci       Date:  1989-05

4.  Recombinant human interleukin-3 and recombinant human granulocyte-macrophage colony-stimulating factor administered in vivo after high-dose cyclophosphamide cancer chemotherapy: effect on hematopoiesis and microenvironment in human bone marrow.

Authors:  A Orazi; G Cattoretti; R Schiró; S Siena; M Bregni; M Di Nicola; A M Gianni
Journal:  Blood       Date:  1992-05-15       Impact factor: 22.113

5.  Novel pentamidine analogs in the treatment of experimental Pneumocystis carinii pneumonia.

Authors:  S K Jones; J E Hall; M A Allen; S D Morrison; K A Ohemeng; V V Reddy; J D Geratz; R R Tidwell
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

6.  A new model of Pneumocystis carinii infection in mice selectively depleted of helper T lymphocytes.

Authors:  J Shellito; V V Suzara; W Blumenfeld; J M Beck; H J Steger; T H Ermak
Journal:  J Clin Invest       Date:  1990-05       Impact factor: 14.808

7.  Pneumocystis carinii: improved models to study efficacy of drugs for treatment or prophylaxis of Pneumocystis pneumonia in the rat (Rattus spp.).

Authors:  M S Bartlett; J A Fishman; M M Durkin; S F Queener; J W Smith
Journal:  Exp Parasitol       Date:  1990-01       Impact factor: 2.011

8.  Cationic antitrypanosomal and other antimicrobial agents in the therapy of experimental Pneumocystis carinii pneumonia.

Authors:  P D Walzer; C K Kim; J Foy; M J Linke; M T Cushion
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

9.  Efficacy of a hydroxynaphthoquinone, 566C80, in experimental Pneumocystis carinii pneumonitis.

Authors:  W T Hughes; V L Gray; W E Gutteridge; V S Latter; M Pudney
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

10.  Requirement for CD4+ cells in resistance to Pneumocystis carinii pneumonia in mice.

Authors:  A G Harmsen; M Stankiewicz
Journal:  J Exp Med       Date:  1990-09-01       Impact factor: 14.307

View more
  6 in total

Review 1.  Prevention of infection due to Pneumocystis carinii.

Authors:  J A Fishman
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

2.  Antibody to Pneumocystis carinii protects rats and mice from developing pneumonia.

Authors:  M S Bartlett; W C Angus; M M Shaw; P J Durant; C H Lee; J M Pascale; J W Smith
Journal:  Clin Diagn Lab Immunol       Date:  1998-01

3.  Neither neutrophils nor reactive oxygen species contribute to tissue damage during Pneumocystis pneumonia in mice.

Authors:  Steve D Swain; Terry W Wright; Peter M Degel; Francis Gigliotti; Allen G Harmsen
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

4.  Semisynthetic echinocandins affect cell wall deposition of Pneumocystis carinii in vitro and in vivo.

Authors:  M S Bartlett; W L Current; M P Goheen; C J Boylan; C H Lee; M M Shaw; S F Queener; J W Smith
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

5.  Vitamin D as Supplemental Therapy for Pneumocystis Pneumonia.

Authors:  Guang-Sheng Lei; Chen Zhang; Michelle K Zimmerman; Chao-Hung Lee
Journal:  Antimicrob Agents Chemother       Date:  2015-12-14       Impact factor: 5.191

6.  Intranasal immunization confers protection against murine Pneumocystis carinii lung infection.

Authors:  J M Pascale; M M Shaw; P J Durant; A A Amador; M S Bartlett; J W Smith; R L Gregory; G L McLaughlin
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.